July 21, 2017
The pharma industry’s reputation among patient groups in the U.S. has sunk to a recent low, and some are pointing to the country’s leader as the reason. Only 29% of groups recently surveyed by research firm PatientView believe pharma has an “excellent” or “good” corporate..
Belgian biotech Ablynx just signed a potentially lucrative new deal with Sanofi that could be worth an eye-watering €2.4 billion, although just €23 million of that comes up front. The new deal is a fillip for Ablynx after AbbVie declined to take up rights to..
U.S. drug distributor Cardinal Health has put its China business up for sale, drawing keen interest from state-backed Chinese pharmaceutical firms in a deal that may be worth up to $1.5 billion, sources familiar with the matter said. Shanghai Pharmaceutical Holding Co Ltd, China Resources..
Amid a noted slowdown in biopharma M&A, fresh comments from Novartis CEO Joe Jimenez signal the challenges facing the industry’s dealmakers. Namely, too-high biotech valuations have forced the Swiss drugmaker’s M&A scouts to eye earlier-stage assets. Jimenez said Tuesday that Novartis is “still very focused..
July 19, 2017
GlaxoSmithKline is looking to unload some marginal businesses and make other cuts that it says will cost about 320 manufacturing jobs in its home country over the next three years. In addition, the company is canceling plans to build a new biologics plant there that..
July 19, 2017
The European Union is investigating whether presubmission meetings with the EMA enable drug companies to influence marketing authorization approval decisions. Officials at the EMA must now allay concerns their meetings with sponsors introduce a source of bias into their decision-making. Drug companies meet with the..
Hundreds of Takeda employees in R&D and vaccines have been asked to relocate from suburban Chicago to the Boston area as part of a two-year effort to position its U.S. jobs in the vibrant scientific hub, according to a new report. As reported by Modern..
As the hemophilia market builds and tensions fray, Shire has signed a new licensing deal targeting bispecific antibodies. Shire and newly-acquired Baxalta have long had medications on the market for the condition, but these are under threat from Roche and its experimental hemophilia A med..
Having served as senior-level executive at such clinical service providers as Exco InTouch and PRA Health Sciences, Steve Powell has taken the helm at SynteractHCR, succeeding Wendel Barr, the CRO’s CEO for the past six years. “[A] respected leader who has built an impressive track..
With Amgen’s competing bone drug now sidelined, Radius has a big opportunity ahead with its Tymlos launch. And the company is staffing up accordingly. Monday, the Massachusetts biotech said it had brought on Jesper Høiland, former president of Novo Nordisk’s U.S. business, as its new..